The effect of hepatic stellate cells on hepatocellular carcinoma progression.

Authors

null

Shuichi Iwahashi

Tokushima University, Tokushima, Japan

Shuichi Iwahashi , Mitsuo Shimada , Yuji Morine , Satoru Imura , Tetsuya Ikemoto , Yu Saito , Shinichiro Yamada , Feng Rui

Organizations

Tokushima University, Tokushima, Japan

Research Funding

Other

Background: The hepatic stellate cells (HSCs) localize at the space of Disse in the liver and have multiple functions. They are identified as the major contributor to hepatic fibrosis. Some manuscripts mentioned that activated HSCs predicted prognoses of hepatocellular carcinoma. The aim of this study is to investigate the effect of HSCs and the role of IL-6 / Stat3 pathway on HCC progression. Methods: HCC cells (Hep G2 and Huh 7) were co-cultured with HSC (LX2 and Li90). The viability and migration ability of cancer cells were detected. Also, the expression of epithelial–mesenchymal transition marker (E-cadherin), stem cell marker (EpCAM and CD44), TGF-b and p-STAT3 of cancer cells were evaluated. Then the IL-6 neutralization was performed during HCC cells and HSCs co-culture. The viability and migration ability of cancer cells were detected. Also, the expression of epithelial–mesenchymal transition marker (E-cadherin), stem cell marker (EpCAM and CD44) and p-STAT3 of cancer cells were evaluated. Results: Co-culture with hepatic stellate cell increased cancer cell viability and migration ability. The expression of E-cadherin, EpCAM and CD44 of cancer cells also increased after co-culture with HSCs. The IL-6 expression and secretion of HSCs were elevated by cancer cell stimulation. The over-expressed IL-6 activated STAT3 of cancer cell showed as the level of phosphorylated STAT3 increased. Neutralized IL-6 during co-culture significantly decrease the viability and migration ability of cancer cells. Also, the expression of E-cadherin, EpCAM and CD44 of cancer cells decreased. Conclusions: HSCs might promote HCC progression through IL-6 / STAT3 pathway.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 265)

DOI

10.1200/JCO.2019.37.4_suppl.265

Abstract #

265

Poster Bd #

E3

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Genitourinary Cancers Symposium

IL-6 and PIM1 expression in renal cell carcinoma.

First Author: Kimberly Stephanie Meza

Abstract

2022 ASCO Genitourinary Cancers Symposium

Targeting an IL-6/JAK/STAT/PIM1 pathway in renal cell carcinoma.

First Author: Kimberly Stephanie Meza

First Author: Rebeca Kelly